Genespire

Genespire is a preclinical stage biotechnology company based in Milan, Italy, co-founded by Fondazione Telethon and Ospedale San Raffaele. The company specializes in developing transformative gene therapies for individuals affected by genetic diseases with high unmet medical needs. Leveraging decades of experience from the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Genespire focuses on inherited metabolic diseases and primary immunodeficiencies (PIDs). The leadership team and scientific founders bring extensive expertise from renowned institutions and biopharmaceutical organizations, ensuring a deep understanding of biological research, drug discovery, and development.

Genespire operates in the biotechnology sector, primarily serving patients with rare genetic disorders. The business model revolves around research and development (R&D) of gene therapies, aiming to bring these therapies to market through clinical trials and regulatory approvals. Revenue generation is anticipated through partnerships, licensing agreements, and eventual commercialization of approved therapies.

Keywords: gene therapy, biotechnology, inherited diseases, metabolic disorders, immunodeficiencies, preclinical stage, Milan, R&D, rare diseases, transformative treatments.